NEW YORK (GenomeWeb) – Transgenomic today announced that it has non-exclusively licensed its portfolio of intellectual property related to DNA susceptibility testing for long QT syndrome to Laboratory Corporation of America.

Long QT syndrome is a primarily congenital heart rhythm disorder associated with cardiac arrhythmia and can be triggered by prescription medicines in individuals prone to the condition.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.